← Leaderboards
Bin Zhang
Beckman Research Institute/City Of Hope
$2,891,856
Attributed
$5,783,711
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,783,711 · 3
By mechanism
R01$5,783,711 · 3
Top collaborators
- Guido Marcucci11 shared
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Guido Marcucci$19,718,636
- Wenyong Chen$3,166,948
- Lihua Elizabeth Budde$959,566
- Jianjun Chen$21,393,583
- Chun-Wei David Chen$8,071,175
Others in their field
Other Emerging Leaders on “Cells”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$155,695,588
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Evan Z Macosko · Broad Institute, Inc.$33,096,828
- James Dale Berry · Brigham And Women'S Hospital$30,122,905
- Hanjoon Ryu$28,519,898
- Eric C Palm · Florida State University$26,502,247
Research focus
CellsIn VivoLeukemiaPlayEffective TherapyDown-RegulationProteinsUntranslated RnaPreventBone MarrowMolecularLeukemic Stem CellMicrornasMessenger RnaDesignHematopoietic Stem CellsHomeostasisSelf-RenewalArterioleFlt3 GeneBlood VesselsEndothelial CellsClinical TrialsAcute Myelocytic Leukemia
Grant awards (11)
Targeting Immune Escape in CML/MPN Transformation$571,615
R01 · FY2025 · CA · contact PI
The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML$542,890
R01 · FY2025 · CA
Targeting Immune Escape in CML/MPN Transformation$571,615
R01 · FY2024 · CA · contact PI
The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML$515,745
R01 · FY2024 · CA
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?$485,048
R01 · FY2024 · CA
The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML$532,031
R01 · FY2023 · CA
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?$500,364
R01 · FY2023 · CA
The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML$542,890
R01 · FY2022 · CA
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?$500,361
R01 · FY2022 · CA
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?$510,576
R01 · FY2021 · CA
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?$510,576
R01 · FY2020 · CA